A Prospective, Single-Arm, Open-Label, Single-Center Clinical Study Evaluating the Efficacy and Safety of Regorafenib Combined with Epacadostat, Tislelizumab, and TACE as First-Line Treatment for Unresectable, Intermediate-to-Advanced Hepatocellular Carcinoma

Start Date31 Jan 2026

Sponsor / Collaborator-

NCT04586244

/ TerminatedPhase 2

An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy

This is a multicenter, open-label, randomized, Phase 2 umbrella study of various neoadjuvant treatment combinations in participants who have muscle-invasive urothelial carcinoma of the bladder and are cisplatin-ineligible or refusing cisplatin therapy and awaiting radical cystectomy.

Start Date14 Jan 2022

Sponsor / Collaborator

Incyte Corp.

NCT04463771

/ CompletedPhase 2

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Start Date26 Jan 2021

Sponsor / Collaborator

Incyte Corp.

[+2]

100 Clinical Results associated with Epacadostat

100 Translational Medicine associated with Epacadostat

100 Patents (Medical) associated with Epacadostat

194

Literatures (Medical) associated with Epacadostat

01 Sep 2026·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Current applications and development of dual-target inhibitors of Ido1/TDO: From tumor immunology to neuropsychiatric disorders

Review

Author: Guo, Wei ; Zhang, Juan ; Jiang, Cheng-Shi ; Zhang, Jing-Zheng ; Wang, Kai-Ming ; Cui, Lu-Yuan

Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are rate-limiting enzymes of the kynurenine pathway and are closely associated with tumor immune evasion and neuropsychiatric disorders. The failure of single-target IDO1 inhibition, exemplified by the phase III setback of epacadostat, has highlighted the limitations imposed by compensatory TDO activity and the heterogeneity of the tumor microenvironment. This review focuses on three generations of IDO1 inhibitors, selective TDO inhibitors, and emerging dual-target strategies, and provides a comprehensive overview of IDO1/TDO dual-target inhibitors. We summarize the research progress of β-carboline, indazole, indole, isoquinoline/alkaloid-derived, and other natural product-related scaffolds, with particular emphasis on their structure-activity relationships, binding modes, translational pharmacology, and preclinical efficacy in tumor and central nervous system models. Clinical-stage candidates have further demonstrated the translational potential of simultaneous IDO1/TDO blockade. Overall, this review offers new insights and strategic perspectives for therapeutic paradigms spanning cancer immunotherapy and neuropsychiatric intervention through modulation of the integrated immunity-metabolism-neurology axis.

01 May 2026·INTERNATIONAL JOURNAL OF UROLOGY

Stage‐Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune‐Related Involvement in Bladder Cancer Progression

Article

Author: Pontes‐Junior, José ; Lemes, Douglas Edgard ; Santos, Aline Áurea de Souza ; Roman‐Ramos, Henrique ; Moreno, Ana Carolina Ramos ; Dellê, Humberto ; de Oliveira, Jéssica Lopes ; Camacho, Cleber Pinto

ABSTRACT:

L‐tryptophan (Trp) metabolism through the L‐kynurenine (Kyn) pathway contributes to immune escape in neoplasms, including bladder cancer (BC). Indoleamine 2,3‐dioxygenase‐1 (IDO1) is a key enzyme, and its catabolites—Kyn, 3‐hydroxykynurenine (3HK), and 3‐hydroxyanthranilate (3HAA)—depend on other enzymes and play a crucial role in immunomodulation.

Objectives:

We investigated the association between Kyn pathway enzyme expression and BC prognostic factors.

Methods:

Data from 165 bc patients in the GEO DataSets were analyzed, comparing staging, tumor grade, progression, and recurrence with the expression of IDO1, arylformamidase (AFMID), kynurenine–oxoglutarate transaminase (KAT), kynureninase (KYNU), kynurenine 3‐monooxygenase (KMO), 3‐hydroxyanthranilate 3,4‐dioxygenase (HAAO), and aminocarboxymuconate‐semialdehyde decarboxylase (ACMSD). Predictive genes were further evaluated in RT4 (low‐grade, non‐invasive) and T24 (high‐grade, invasive) BC cells treated with IFN‐gamma and the IDO1 inhibitor INCB024360. Trp catabolites were quantified in the supernatant.

Results:

Enzyme expression varied widely, especially for IDO1, AFMID, KAT, KMO, and KYNU. IDO1 correlated positively with KMO and negatively with KAT. High IDO1 and KMO levels were linked to advanced‐stage disease, while KAT and KYNU were associated with earlier stages and lower tumor grade. RT4 and T24 cells showed distinct basal enzyme expression, with T24 cells being more responsive to IFN‐gamma, increasing IDO1 and KYNU while decreasing KAT and KMO. These effects were inhibited by INCB024360. High Trp consumption increased Kyn and 3HAA but not 3HK.

Conclusions:

Kyn pathway enzyme expression varies with disease progression and may indicate immune activity by influencing tumor microenvironment catabolites. BC cell sensitivity to immune stimuli differs, potentially shaping distinct immune escape mechanisms.

02 Nov 2025·Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery

Expression of indoleamine-2,3-dioxygenase 1 in sebaceous glands and related tumors of the eyelid: a potential diagnostic target

Article

Author: Raul Hernandez-Rubio ; Kenneth Morgenstern ; Lisa D. Laury-Kleintop ; Narmien Murdock ; Alexander J. Müller ; Jan P. Ulloa-Padilla ; Cat N. Burkat ; Jacqueline Carrasco

PURPOSE:

Mechanisms that modulate the immune response hold great potential as viable strategies for combating cancer. Among these, novel molecular compounds that inhibit IDO1 have emerged as one of the most promising therapeutic opportunities for impeding tumor growth. The present objective is to describe the expression of indoleamine-2,3-dioxygenase 1 (IDO1) in sebaceous glands and study its role in diagnosing sebaceous carcinoma of the eyelid.

METHODS:

We conducted a clinical-pathologic study of IDO1 expression in healthy sebaceous glands, sebaceous adenomas (SA), sebaceous hyperplasia (SH), and sebaceous carcinoma (SC). A comparison of immunohistochemical staining intensity and distribution for IDO1 was performed between all groups. Clinical data was correlated with IDO1 staining.

RESULTS:

The study included 38 patients: 6 controls, 5 SA, 6 SH, and 18 SC. The mean H-scores of the control group, SA, SH, and SC were 0, 110, 127.5, and 201.9, respectively. There was a significant relationship between IDO1 h-scores and both patient age and tumor stage (p-values <0.001). There was a significant increase in IDO1 expression between SC and all other groups.

CONCLUSIONS:

Our study demonstrated a statistically significant upregulation and reactivity of IDO1 in sebaceous gland tumors. Prior to these findings, clinical management centered around surgical excision. The use of molecular compounds such as indoximob, epacadostat, BMS-986205 and navoximod, that directly target IDO1 opens new possibilities for targeting these tumors, improving clinical outcomes, and minimizing the morbidities often associated with surgery.

News (Medical) associated with Epacadostat

13 Oct 2025

·www.fiercebiotech.com

Moderna posts melanoma data behind decision to say \'I do\' to IDO

Moderna studied two doses of mRNA-4359, which encodes PD-L1 and IDO antigens, in combination with Merck & Co.’s blockbuster oncology drug Keytruda.\n Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.The data, which Moderna will present at the 2025 European Society for Medical Oncology Congress later this week, come from 29 patients with relapsed or refractory melanoma. All the patients had advanced after trying at least one PD-1/L1 checkpoint inhibitor. Moderna studied two doses of mRNA-4359, which encodes PD-L1 and IDO antigens, in combination with Merck & Co.’s blockbuster oncology drug Keytruda.The objective response rate was 24% in evaluable patients who received mRNA-4359 intramuscularly every three weeks for up to nine doses. Adding in patients with stable disease resulted in a 60% disease control rate. The trial is yet to reach the median duration of response.Moderna saw responses in six of the nine evaluable patients with PD-L1-positive tumors. Keytruda’s label in melanoma covers all levels of PD-L1, but an expression threshold applies in some other tumor types. Moderna said the subgroup analysis supports PD-L1 as a potential predictive biomarker in a high unmet need population. The data drop follows the publication of monotherapy data last year. Moderna sees targeting PD-L1 and IDO as a way to train the immune system to kill a tumor and tackle the immunosuppression that can limit the impact of immune attacks. Kyle Holen, M.D., head of development, therapeutics and oncology at Moderna, set out how the dual mechanism of action differentiates mRNA-4359 from existing drugs.“Where other checkpoint inhibitors restore non-specific T cell activity, mRNA-4359 encodes two critical immune escape pathways to help generate new, target-directed T cells,” Holen said in a statement. “This could enable broader and more durable immune responses for patients who have not had success with prior lines of therapy.”Multiple companies have identified IDO as a target that could complement PD-1/L1 drugs, but the failure of Incyte’s epacadostat triggered a retreat from programs focused on the enzyme. IO Biotech was among the companies that continued to see a future for IDO. However, a phase 3 study of IO’s cancer vaccine missed its primary endpoint in August, and the FDA later advised the biotech against seeking approval.Rose Loughlin, Ph.D., executive vice president of research at Moderna, commented on the competition at a Bernstein event last month. Noting differences between Moderna and IO’s platforms and antigens, Loughlin said the rival data helped derisk mRNA-4359 and encouraged the mRNA specialist “to continue aggressively developing in that space.”

$Moderna posts melanoma data behind decision to say \'I do\' to IDO$

Phase 3Clinical ResultmRNAVaccinesiRNA

08 May 2023

·www.prnewswire.com

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs

DUBLIN, May 8, 2023 /PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer- Competitive landscape, 2023" report provides comprehensive insights about 250+ companies and 300+ drugs in Pancreatic Cancer Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, Adaptimmune Therapeutics plc. and TCR Therapeutics Inc. (NASDAQ: TCRR), announced entry into a definitive agreement under which Adaptimmune will combine with TCR in an all-stock transaction to create a preeminent cell therapy company focused on treating solid tumors. The combination provides extensive benefits for clinical development and product delivery supported by complementary technology platforms. As a result, and following the closing of the transaction, it is anticipated that the combined company's cash runway will extend into 2026. In February 2023, Akamis Bio, announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer. As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY). In February 2023, Gritstone bio, Inc. announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone's KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study. Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). In February 2023, Keymed Biosciences Inc., jointly announced a global exclusive license agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). Under the license agreement, AstraZeneca will be responsible for the research, development, manufacture and commercialization of CMG901 globally. CMG901 is currently in a Phase I clinical trial for the treatment of Claudin 18.2-positive solid tumors. In January 2023, AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca. Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech. Pancreatic Cancer Analytical Perspective In-depth Commercial Assessment: Pancreatic Cancer Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Key Questions Answered Current Treatment Scenario and Emerging Therapies: How many companies are developing Pancreatic Cancer drugs? How many Pancreatic Cancer drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Pancreatic Cancer and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Panbela Therapeutics ERYtech Pharma Jiangsu HengRui Medicine Co., Ltd. FibroGen Novartis AG AB Science TME Pharma AG Intensity Therapeutics Silenseed LTD SynerGene Therapeutics Elevation oncology Salspera LLC Redx Pharma Plc AIM ImmunoTech Inc. Rain Oncology Jazz Pharmaceuticals Invyte Corporation Immodulon Therapeutics Ltd GSK plc Merck Sharp & Dohme LLC Roche Helsinn Healthcare SA Argenus Inc. Actuate Therapeutics OSE Immunotherapeutics Incyte Corporation Galera Therapeutics CSPC ZhongQi Pharmaceutical Technology Astellas Pharma Global Development, Inc. NanOlogy Theriva Biologics AstraZeneca Berg, LLC Agenus ABVC BioPharma, Inc. Boehringer Ingelheim Alligator Bioscience CARsgenTherapeutics Co.,Ltd Purple Biotech Ltd. Lisata Therapeutics Chongqing Precision Biotech Co., Ltd Cybrexa Therapeutics Bold Therapeutics BioNTech SE Bristol-Myers Squibb DEKA Biosciences Senhwa Biosciences Cue Biopharma Carisma Therapeutics Inc Key Products Olaptesed pegol INT230-6 SBP-101 Masitinib NIS793 siG12D LODER SGT-53 Seribantumab Salmonella-IL2 RXC004 Rintatolimod RAIN-32 Lurbinectedin Retifanlimab IMM-101 GSK2256098 Belzutifan Atezolizumab Anamorelin AGEN1423 Elraglusib OSE2101 Epacadostat GC4711 Docetaxel Zolbetuximab NanoPac VCN-01 Danvatirsen BPM31510 Botensilimab ABV-1703 BI 907828 Mitazalimab CT041 CM24 CEND-1 CEA-targeted CAR-T cells CBX-12 BOLD-100 BNT141 BMS-813160 DK210 CX-5461 CUE-102 CT-0508 For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

ImmunotherapyLicense out/inVaccinePhase 1ADC

21 Dec 2022

·www.prnewswire.com

Gastric Cancer Pipeline Space Brims With Novel Emerging Therapies with Over 200 Key Companies Working in the Domain | DelveInsight

The prevalence of gastric cancer has been rising since the past few years, which prompts the growing demand for treatment options. The increasing prevalence of cancer, the robust pipeline, and the growing research and development activities to develop novel therapies to treat Gastric Cancer drive the market. The companies developing the potential therapies in the last stage of development include Henlix Biotech, Eli Lilly and Company, Jiangsu Hengrui Medicine, and several others. LAS VEGAS, Dec. 21, 2022 /PRNewswire/ -- DelveInsight's ' Gastric Cancer Pipeline Insight – 2022 ' report provides comprehensive global coverage of available, marketed, and pipeline gastric cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the gastric cancer pipeline domain. Key Takeaways from the Gastric Cancer Pipeline Report DelveInsight's gastric cancer pipeline report depicts a robust space with 200+ active players working to develop 230+ pipeline therapies for gastric cancer treatment. Key gastric cancer companies such as EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others are evaluating new gastric cancer drugs to improve the treatment landscape. Promising gastric cancer pipeline therapies in various stages of development include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others. In December 2022, Daiichi Sankyo and AstraZeneca's ENHERTU (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In December 2022, RemeGen Co., Ltd. announced on December 7, 2022, that its latest antibody-drug conjugate (ADC), RC118 for injection, has been granted two orphan drug designations (ODD) by the United States Food and Drug Administration (FDA) for gastric cancer (including gastroesophageal junction cancer) and pancreatic cancer. This marks the Company's fourth, having previously been twice granted ODD for Disitamab Vedotin (RC48) and Telitacicept (RC18) earlier this year. In December 2022, Zhejiang Doer Biologics Co., Ltd. announced that it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), to investigate Doer Bio's anti-Claudin18.2 antibody DR30303, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with Gastric or Gastroesophageal Junction Cancer. Under this agreement, Doer Bio will conduct a clinical study based on a mutually- agreed and finalized protocol to evaluate the safety and efficacy of DR30303 in combination with KEYTRUDA® in patients with Claudin18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GC/GEJ) cancer. In November 2022, Triumvira Immunologics announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data on HER2-specific TAC-T products. Data was shared in three posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held virtually and in-person in Boston.Triumvira announced updated data on its novel T cell antigen coupler (TAC)-T cell candidate targeting Claudin 18.2 (CLDN18.2) for the treatment of gastric cancer. The data continue to demonstrate that CLDN18.2-TAC T effectively eliminates CLDN18.2-expressing gastric cancer cells in vitro and in vivo. The study also demonstrated that the activation of CLDN18.2-TAC T cells was specific to target cells that expressed CLDN18.2. In vitro data show strong and persistent anti-tumor activity and in vivo treatment led to complete and sustained tumor clearance with no signs of toxicity. In September 2022, Nuvectis Pharma, Inc. announced positive data for NXP800 in a preclinical xenograft model of ARID1a-mutated gastric carcinoma.Mice in each group were treated with either vehicle or NXP800, and tumor volumes were measured over 28 days. Treatment with NX800 resulted in tumor regression and substantial tumor growth inhibition versus the control. In March 2022, Imugene (ASX: IMU) announced a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA®), in patients with HER-2 positive gastric cancer. Request a sample and discover the recent advances in gastric cancer drug treatment @ Gastric Cancer Pipeline Report The gastric cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage gastric cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the gastric cancer clinical trial landscape. Gastric Cancer Overview Stomach cancer is cancer that begins within the stomach or on the stomach wall. It is also known as gastric cancer. Stomach cancer is more common in the elderly. People aged 75 and above account for approximately 50 out of every 100 cases (around 50%). It affects men more than women. The exact gastric cancer causes are not known. Stomach cancer is linked to Helicobacter pylori, a bacteria that lives in the stomach. The most common gastric cancer symptoms are difficulty swallowing (dysphagia), weight loss, persistent indigestion (dyspepsia), feeling full after eating small amounts, feeling or being sick, and fatigue due to low red blood cell count (anaemia). Several tests, such as ultrasound, imaging tests, blood tests, and others, are used for gastric cancer diagnosis. Gastric cancer patients can receive a variety of treatments. Standard gastric cancer treatment consists of seven types: surgery, endoscopic mucosal resection, chemotherapy, radiation therapy, chemoradiation, targeted therapy, and immunotherapy. Find out more about chemotherapy drugs for gastric cancer @ New Gastric Cancer Drugs A snapshot of the Gastric Cancer Pipeline Drugs mentioned in the report: Learn more about the emerging gastric cancer pipeline therapies @ Gastric Cancer Clinical Trials Gastric Cancer Therapeutics Assessment The gastric cancer pipeline report proffers an integral view of gastric cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Gastric Cancer Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants, Apoptosis stimulants, Macrophage stimulants, Natural killer cell stimulants, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, Angiogenesis inhibitors, Epidermal growth factor receptor antagonists, EIF 2 kinase inhibitors Key Gastric Cancer Companies: EMD Serono, Sumitomo Pharma, LintonPharm Co., Ltd., Rapa Therapeutics LLC, Jiangsu HengRui Medicine Co., Ltd., Janssen Pharmaceutical K.K., Genentech, Exelixis, Bristol-Myers Squibb, Pieris Pharmaceuticals, Inc., Pfizer, Leap Therapeutics, CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, LianBio LLC, Chengdu Kanghong Biotech,Eisai Inc., AB Science, Maxinovel Pharmaceuticals, Shanghai Miracogen Inc., GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Hutchison Medipharma Limited, Genome & Company, Minneamrita Therapeutics LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., MacroGenics, ALX Oncology Inc., Codiak BioSciences, Turning Point Therapeutics, Inc., TCRx Therapeutics, InxMed (Shanghai) Co., Ltd., Imugene Limited, SOTIO Biotech, CARsgen Therapeutics Co., Ltd., Zymeworks Inc., NextCure, Inc., Phanes Therapeutics, Pieris Pharmaceuticals, Inc., Athenex, Inc., Curis, Inc., Qurient Co., Ltd., Acepodia Biotech, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Tarus Therapeutics, Inc., Lumicell, Inc., Legend Biotech,Cue Biopharma, TORL Biotherapeutics, LLC, OBI Pharma, Inc, Astellas Pharma, HiberCell, Inc., Celon Pharma SA, Linnaeus Therapeutics, Inc., Inspirna, Inc., Klus Pharma Inc., Genzada Pharmaceuticals, Shanghai PerHum Therapeutics, VM Oncology, LLC, Immunomic Therapeutics, Peptron, and others. Key Gastric Cancer Pipeline Therapies: Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022, TCRx_T Cells, IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410, PT 886, PRS-343, Oraxol, CA-4948, Q702, ACE1702, SI-B001, TT-4, LUM015, LB 1908, CUE-102, TORL-2-307-MAB, OBI-833/OBI-821, ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110, LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453, CCT303-406, VMD-928, ITI 4000, PAb 001, and others. Dive deep into rich insights for new drugs for gastric cancer treatment; visit @ Gastric Cancer Medications Table of Contents For further information on the gastric cancer pipeline therapeutics, reach out @ Gastric Cancer Drug Treatment Related Reports Gastric Cancer Epidemiology Forecast Gastric Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the gastric cancer epidemiology trends. Gastric Cancer Market Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including CSPC ZhongQi Pharmaceutical, Ellipses Pharma, Amgen, Hanmi Pharmaceutical, Taiho Oncology, Inc., Shanghai Henlius Biotech, among others. HER2+ Gastric Cancer Market HER2+ Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2+ gastric cancer companies, including Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc, among others. HER2+ Gastric Cancer Pipeline HER2+ Gastric Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key HER2+ gastric cancer companies, including Pieris Pharmaceuticals, BioInvent International, Bellicum Pharmaceuticals, Mersana Therapeutics, Acepodia Biotech, Inc., Klus Pharma Inc, among others. HER2+ Gastric Cancer Epidemiology HER2+ Gastric Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the HER2+ gastric cancer epidemiology trends. Other Trending Oncology Reports Follicular lymphoma | Indolent lymphoma | Severe Toxicities In Lymphoma | Marginal Zone Lymphoma | Vulvar Squamous Cell Carcinoma | Cholangiocarcinoma | Metastatic Cutaneous Squamous cell Carcinoma | Nasopharyngeal Carcinoma | Ductal Carcinoma in Situ | Oncolytic Virus Cancer Therapy | Cancer Cachexia | Intratumoral Cancer Therapies | Brain Cancer Related Cases Studies Competitive Intelligence Market Assessment Product Assessment Epidemiology Assessment Related Healthcare Services Healthcare Business Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

ImmunotherapyOrphan DrugDrug Approval

100 Deals associated with Epacadostat

External Link

KEGG	Wiki	ATC	Drug Bank
D11049	Epacadostat	L01XX58	DB11717

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	United States	Incyte Corp.	27 Dec 2017
Recurrent Non-Small Cell Lung Cancer	Phase 3	United States	Incyte Corp.	27 Dec 2017
Metastatic urothelial carcinoma	Phase 3	United States	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Japan	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Australia	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Canada	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Denmark	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	France	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Germany	Incyte Corp.	22 Dec 2017
Metastatic urothelial carcinoma	Phase 3	Hungary	Incyte Corp.	22 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03532295 (CTIM-23, CTgov)	Phase 2	Glioblastoma Multiforme \| Glioblastoma \| Recurrent Glioblastoma	51	Radiation therapy+Bevacizumab+Retifanlimab (Regimen A: Retifanlimab+RT+bevacizumab)	jwmlodcusk = xhcuhczwss ivjasrrpdz (argupwepqz, lupbjxlbcj - uaryctxoup) View more	-	07 Aug 2025
				Radiation therapy+Bevacizumab+Epacadostat+Retifanlimab (Regimen B: Retifanlimab+RT+bevacizumab+epacadostat)	jwmlodcusk = lhrgnhxzds ivjasrrpdz (argupwepqz, aykawxamkf - piltmglrkt) View more
NCT03493945 (QuEST1, CTgov)	Phase 1/2	Locally Advanced Malignant Solid Neoplasm \| Advanced Malignant Solid Neoplasm	59	castration+M7824+BN-Brachyury (Phase IIA Dose Expansion (Dose Exp.), Cohort 2, Arm 2.1A)	chwrupnwhe = fddsrkeoom cjthpjgcjc (wwtehtwrzl, uhbhbdziip - twixlgyajj) View more	-	08 Jun 2025
				N-803+M7824+BN-Brachyury (All Participants in Phase IIA Dose Expansion and Phase IIB Dose Expansion)	chwrupnwhe = mcrolppbhl cjthpjgcjc (wwtehtwrzl, aikgujwmkk - msdotyumpk) View more
NCT03414229 (CTgov)	Phase 2	Malignant Fibrous Histiocytoma \| Leiomyosarcoma \| Hemangiosarcoma ... View more	30	Pembrolizumab+Epacadostat (UPS, Liposarcoma or Pleomorphic Liposarcoma)	qgwnqcrpcn = ycyvevkbbe tglfucvuim (cwddrdxlyw, gynnskrqkm - bxbwcwdplk) View more	-	02 May 2025
				Pembrolizumab+Epacadostat (Leiomyosarcoma)	qgwnqcrpcn = jnelcepyjv tglfucvuim (cwddrdxlyw, ucmxxqgbuy - alraqqmffi) View more
NCT04586244 (Optimus, CTgov)	Phase 2	Muscle Invasive Bladder Urothelial Carcinoma	30	Epacadostat+Retifanlimab (Epacadostat 600 mg BID + Retifanlimab 500 mg Q4W)	mxbazgfehg = odzfevirub qsysdkitbn (muhgjegbqk, dqlqxxiyfk - jenjgcttlm) View more	-	10 Mar 2025
				Retifanlimab (Retifanlimab 500 mg Q4W)	vvoxxbrxwh(xxvxexjssk) = yojntvvgqi icdryhomuq (lirwwjgtew, 0.9332) View more
NCT03322540 (Pubmed) Manual	Phase 2	PD-L1 positive Non-Small Cell Lung Cancer First line PD-L1	154	pembrolizumab0Epacadostat	usvfhvahou(cnaedngflm) = xuutmsdlus vntehamipc (lncotwfnue, 22.2 - 44.1) View more	Negative	25 Jul 2024
				pembrolizumab	usvfhvahou(cnaedngflm) = lmantjnyiw vntehamipc (lncotwfnue, 28.0 - 50.8) View more
NCT03374488 (ECHO-303 \| KEYNOTE-698, Pubmed \| BMC Cancer) Manual	Phase 3	Advanced Urothelial Carcinoma Second line	42	Epacadostat 100 mg BID plPembrolizumabmab	lazpumwisu(ndfxqpdgyt) = fnofpvfbzx iypbpbjmta (lpkttohauj, 16.35 - 48.11) View more	Positive	25 Jul 2024
				Placebo plPembrolizumabmab	lazpumwisu(ndfxqpdgyt) = yuuesyyxwz iypbpbjmta (lpkttohauj, 4.67 - 29.50) View more
NCT03322566 (ECHO-306/KEYNOTE-715, Pubmed) Manual	Phase 2	metastatic non-small cell lung cancer First line PD-L1 tumor proportion score \| tumor histology	178	Epacadostat-Pembrolizumab-Chemotherapy	vdcsbdmccg(dftakfsksv) = mevmmkswub xmbldaymeo (qafyxirpud, 17.7 - 36.7) View more	Negative	25 Jul 2024
				Placebo-Pembrolizumab-Chemotherapy	vdcsbdmccg(dftakfsksv) = zspbzoajvp xmbldaymeo (qafyxirpud, 34.1 - 55.9) View more
NCT03260894 (KEYNOTE-679/ECHO-302, Pubmed \| BMC Cancer) Manual	Phase 3	Metastatic Renal Cell Carcinoma First line	129	Pembrolizumab plus epacadostat	mpjdgdwgfk(gzqqtxndzx) = kkryurstlr oyyjvczebr (vedcbsytgy, 20.2 - 44.1) View more	Negative	25 Jul 2024
				Sunitinib or pazopanib	mpjdgdwgfk(gzqqtxndzx) = zkqahiwmnl oyyjvczebr (vedcbsytgy, 18.6 - 41.8) View more
NCT03358472 (KEYNOTE-669/ECHO-304, Pubmed \| BMC Cancer) Manual	Phase 3	Squamous Cell Carcinoma of Head and Neck	89	Pembrolizumab plus epacadostat	toxuwtaoed(mymtoackjj) = ysdbxdkwmg kvqwzmvoql (ujugtmaaon, 17 - 49) View more	Positive	25 Jul 2024
				Pembrolizumab monotherapy	toxuwtaoed(mymtoackjj) = ybmjmesdiu kvqwzmvoql (ujugtmaaon, 6 - 46) View more
NCT03361865 (ECHO-307/KEYNOTE-672, Pubmed \| BMC Cancer) Manual	Phase 3	Transitional Cell Carcinoma First line circulating kynurenine levels	93	Epacadostat plus Pembrolizumab	zaheyoywmk(cfwrubtkwn) = acwwxbvbix jjnaerksnm (ziedevxdbs, 22.46 - 55.24) View more	Negative	25 Jul 2024
				Placebo plus Pembrolizumab	zaheyoywmk(cfwrubtkwn) = qbdtgqorbd jjnaerksnm (ziedevxdbs, 15.33 - 43.67) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis